Keyword: Versant Ventures
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.
The appointment puts Phil Vickers, Ph.D., in charge of the Celgene-partnered biotech as its lead immuno-oncology asset closes in on the clinic.
New startup biotech Oyster Point Pharmaceuticals came out of stealth today with $22 million led by venture capital firms New Enterprise Associates (NEA) and Versant Ventures.
The round equips a team last seen leading Okairos to a €250 million buyout by GSK to take off-the-shelf neoantigen cancer vaccine into the clinic.
The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.
GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.
Repare Therapeutics has emerged from stealth mode with an impressive $68 million.
VC Versant has pumped $20 million on its own into its newly launched preclinical liver disease upstart Jecure, with its founders coming out from a former Versant biotech.
Anokion is in line to be snapped up by serial dealmaker Celgene as the Big Biotech pays $45 million upfront with an M&A clause built in for the Big Pharma-backed autoimmune disease specialist.